Eicosapentaenoic acid/docosahexaenoic acid/statin

Drug Profile

Eicosapentaenoic acid/docosahexaenoic acid/statin

Alternative Names: Epanova/statin; Fixed dose combination Epanova/statin

Latest Information Update: 08 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Docosahexaenoic acids; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action HMG-CoA reductase inhibitors; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Hypercholesterolaemia; Hypertriglyceridaemia

Most Recent Events

  • 06 May 2014 Investigation in Hypercholesterolaemia in United Kingdom (PO)
  • 06 May 2014 Investigation in Hypertriglyceridaemia in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top